3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Melanoma
3
Brain Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Colorectal Neoplasms
2
Advanced Cancer
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Interventions
Gemcitabine
6
Pemetrexed
3
Cisplatin
3
Carboplatin
3
atezolizumab
2
Trastuzumab
2
Sugammadex
2
Paclitaxel
2
Neostigmine
2
vinflunine
1
poly ICLC
1
pembrolizumab
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
delta 24-sterol reductase
1
daratumumab
1
avelumab
1
apatorsen
1
abemaciclib
1
Water
1
Thalidomide
1
Surveys and Questionnaires
1
Saline Solution
1
Rocuronium
1
Nephroureterectomy
1
Nephrectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urologic Neoplasms
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled